The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Vaccines are the key technology to combat existing and emerging infectious diseases.
However, increasing the potency, quality and durability of the vaccine response remains a …

Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been
induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare …

Vaccines generate high-affinity antibodies by recruiting antigen-specific B cells to germinal
centers (GCs), but the mechanisms governing the recruitment to GCs on secondary …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
stresses the continued need for next-generation vaccines that confer broad protection …

Vaccines are critical tools for maintaining global health. Traditional vaccine technologies
have been used across a wide range of bacterial and viral pathogens, yet there are a …

Germinal center (GC) B cells are the source of the high-affinity, class-switched antibodies
required for protective immunity. The unique biology of GC B cells involves iterative rounds …

Saponins are potent and safe vaccine adjuvants, but their mechanisms of action remain
incompletely understood. Here, we explored the properties of several saponin formulations …

Modern vaccine design has sought a minimalization approach, moving to the isolation of
antigens from pathogens that invoke a strong neutralizing immune response. This approach …

Nanoparticles for multivalent display and delivery of vaccine antigens have emerged as a
promising avenue for enhancing B cell responses to protein subunit vaccines. Here, we …